Key takeaways:

• Compliance is a starting point, not proof of control. Pharma leaders need AI governance in pharma to understand how models behave, who owns outcomes and where risk requires intervention.
• AI risk management should move with the model. As AI systems learn and drift, teams need monitoring, escalation rules and human accountability built into daily operating rhythms.
• Trust depends on knowing when people must step in. AI model monitoring and oversight helps teams catch weak signals, question outputs and act before risk spreads.

The pharmaceutical industry has endured a long history of regulatory pressure that requires organizations to prove they are meticulous, audit-ready and defensible. This discipline is valuable. But when it comes to AI, compliance alone can’t guarantee safe or effective use.

As AI begins to influence critical areas in pharma, such as clinical trial design and drug safety monitoring, a fundamental shift is required to maintain control over the new workflows and outputs it creates.

The real challenge and opportunity now lie in moving from compliance to control.

Compliance in an AI-driven world

When new technologies enter regulated environments, organizations tend to continue reliance on familiar playbooks to validate their use. They establish policies for the new systems, document processes and ensure audit readiness. This approach works well for static systems, but AI is fundamentally different.

In traditional systems, validation provides confidence because behavior is predictable. With AI, this assumption doesn’t hold.

This is where the “compliance trap” emerges. A system may be fully validated and documented by IT or analytics teams, yet still poorly understood by the commercial or medical teams expected to use and control it.

AI systems are dynamic and don't operate in fixed, linear processes. They learn, evolve and sometimes drift over time.

In AI-driven workflows, the process itself can change based on context, risk thresholds and real-time decisioning, making static oversight insufficient. AI can influence decisions at multiple points, which means risk and relevance must be controlled continuously rather than assumed at a single validation checkpoint.

Risks and failures aren’t always immediate or visible, sometimes surfacing after downstream consequences emerge. In some cases, what appeared to be a compliant asset in the beginning can become a significant risk.

Compliance provides a record of what has been done. But it doesn’t guarantee that organizations can anticipate, detect or respond to issues as they arise. True control, on the other hand, gives teams the ability to act before problems escalate.

Why compliance isn’t enough

A validated AI model that no one fully understands doesn’t represent control. It represents exposure. Without visibility into how outputs are generated and how the model evolves and makes decisions, organizations can’t intervene effectively.

In pharma, where decisions have a direct impact on patient safety and regulatory standing, this gap is particularly critical. Relying solely on compliance creates a false sense of security.

What’s needed instead is for pharma commercial and medical leaders to have more control of AI models by developing a deeper, operational understanding of their behavior over time:

• What is AI looking for when it monitors and structures data?
• How is it contextualizing data to surface recommendations?
• Is it clearly explaining why it’s taking each action?

What control of AI in pharma looks like

Moving from compliance to control requires a shift in how organizations engage with AI, not just how they document it. Three elements are essential:

1. Interpretability

Black-box models aren’t acceptable in environments where decisions affect patient outcomes or regulatory approvals. Stakeholders need to understand how and why an AI system produces its outputs through clear, plain-language reasoning.

AI systems must offer self-serve, conversational explanations of the context they use to make decisions and show how they remain compliant.

2. Accountability

AI systems don’t own decisions. People do. Clear human ownership must be established at each step of every AI-informed outcome. Control is required for review, approval and execution to ensure responsibility remains with the organization, not the model.

When leaders step in to mitigate inconsistencies in these processes early on, risk lessens, AI learns to produce more accurate results and teams become more invested in the system and workflows.

3. Adaptive governance

As AI systems evolve, governance must evolve with them. Static, point-in-time validation approaches quickly become outdated. Instead, organizations need oversight mechanisms and auditability that continuously adapt alongside the technology across markets and regulatory environments.

Governed workflows, role-based access, auditability and explainable AI provide transparency into inputs, outputs and decision logic that help leaders scale AI safely.

Together, these elements enable pharma organizations to move beyond passive oversight and toward active management of their AI systems.

Trust and control in AI can’t be achieved through documentation alone. It must be built through continuous understanding, monitoring and action.

Getting there: Practical steps to move from compliance to control

Knowing what control requires is only the starting point. The harder question is how organizations actually build it. The following steps offer a practical path forward.

Conduct an AI inventory with accountability owners. Start by mapping every AI system in use across commercial and medical functions, not just the ones IT approved. For each, assign a named business owner responsible for outputs and outcomes. This step alone surfaces the accountability gaps that compliance frameworks routinely miss.

Demand explainability as a procurement requirement. Before deploying or renewing any AI system, require vendors to demonstrate that outputs can be explained in plain language to a non-technical stakeholder. If a model can't explain why it surfaced a particular recommendation, it shouldn’t be trusted to influence patient-facing or regulatory decisions.

Build monitoring into operating rhythms, not audit cycles. Model drift doesn't wait for the next compliance review. Embed lightweight monitoring checkpoints into existing business reviews, including quarterly brand planning, field force performance calls and safety signal reviews. The goal isn’t a separate AI audit. The goal is making AI performance a standing agenda item where the business already pays attention.

Establish escalation triggers before you need them. Define in advance the conditions under which a model gets paused, retrained or shut down, along with who has authority to make that call. Organizations that wait until something goes wrong to have this conversation lose valuable response time. Pre-agreed thresholds make intervention faster and less contentious.

Train commercial and medical teams, not just IT. Control is only possible when the people closest to AI outputs understand what they are seeing. This doesn’t require technical fluency. It requires enough operational literacy to recognize when an output looks wrong, ask the right questions and know where to escalate. That capability is built through training, not assumed through deployment.

None of these steps requires a large-scale transformation program. They require deliberate choices about ownership, transparency and oversight. These choices are already within reach for pharma organizations.

Organizations that succeed with AI in pharma won't be those that simply check compliance boxes. They’ll be the ones that invest in truly understanding their systems, including how they behave, when they drift and when they need intervention.

Enabling faster, more confident innovation

Contrary to common assumptions, stronger control doesn’t slow organizations down. It accelerates them.

When commercial and medical teams trust their AI systems, they are more confident in scaling use cases and making decisions based on AI-driven insights. This trust also holds up under regulatory scrutiny, enabling organizations to innovate without hesitation.

Rather than second-guessing outputs or limiting adoption, controlled AI environments encourage broader and more impactful applications.

From compliance to ownership

The shift from compliance to control isn’t about increasing documentation or adding complexity. It’s about taking ownership.

Ownership means understanding systems deeply, maintaining accountability for outcomes and building governance models that evolve with technology. It places responsibility firmly within the organization rather than outsourcing it to evolving processes or outdated validations.

In an industry where regulatory stakes are as high as they are in pharma, this level of ownership isn’t optional. It’s essential.

As AI becomes increasingly embedded in pharmaceutical operations, the question is no longer whether organizations are compliant. The real question is whether they are in control.

Organizations that make this shift won’t only mitigate risk. They’ll realize AI’s full potential with the confidence and clarity needed to lead in a rapidly evolving landscape.